Podcasts about molecular

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

What happens when you combine frontier AI, agentic systems, and quantum computing?In this episode of NEXT with John Koetsier, we chat with Mykola Maksymenko, co-founder and CTO of Haiqu, about how AI agents are dramatically accelerating quantum research and potentially scientific discovery as a whole.Maksymenko shares how an AI system was able to reconstruct months of his own PhD research in a fraction of the time, even identifying a bug in one of his formulas. He also discusses experiments involving genomics, molecular simulation, quantum chemistry, and condensed matter physics.The bigger question: do we really need to wait for fault-tolerant quantum computers with hundreds or thousands of logical qubits before quantum computing becomes useful?Maksymenko argues that useful quantum applications are already emerging today, particularly when AI agents help scientists discover algorithms, orchestrate workflows, and handle the complexity of working with noisy quantum hardware.We also explore the risks of increasingly capable AI systems, scientific guardrails, quantum utility versus quantum supremacy, and what happens when researchers can test ideas in a weekend that previously might have required months or years.Topics include:• Agentic AI for scientific research• Quantum utility vs. quantum supremacy• AI-assisted genomics• Quantum chemistry and molecular dynamics• Automating quantum software workflows• AI as a scientific collaborator and educator• The risks and guardrails of frontier AI• Why scientific discovery could accelerate dramatically00:00 — “I think AGI is here” 00:40 — Meet Mykola Maksymenko 01:01 — Why a quantum physicist started experimenting with genomics 02:18 — Reproducing years of research with AI and quantum computing 03:07 — The convergence of AI, agents, and quantum computers 04:26 — Are we entering the singularity? 04:45 — AI reconstructs six months of PhD research 05:28 — The risks of AI-assisted genomics and scientific discovery 06:46 — Pandora's box and the race for frontier AI 07:02 — What researchers are doing with the technology now 08:29 — Can quantum computers already do useful work? 09:21 — From quantum supremacy to quantum utility 11:06 — Molecular dynamics and quantum chemistry 12:12 — The minimum viable product of quantum computing 13:00 — Why Haiku moved deeper into agentic AI 13:30 — How much faster can AI make scientific research? 15:47 — AI as a scientist's educator and collaborator 16:51 — Running research experiments over a weekend 17:16 — What happens next for AI + quantum computing 17:38 — How AI agents operate quantum computers 18:59 — Closing thoughts

Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal Investigator at Calico Life Sciences, building a research lab on the biology of ageing and helping grow the company from 15 to more than 200 people, and holds a PhD in Molecular and Cell Biology from UC Berkeley. You'll get a working model for how Arda's discovery engine turns single-cell and spatial transcriptomic data into causal cell targets. Adam explains why a common statistical shortcut in single-cell analysis produces disease signals that don't hold up and how cell depletion could replace daily dosing with a handful of treatments that reset the immune system. Ross and Adam cover how Arda finds pathogenic cell populations across hundreds of donors, why chi-squared tests on cell clusters can substitute cell count for donor count without anyone noticing, and how B-cell depletion therapies proved that removing a cell can beat blocking its pathway. This one is for data science leaders and computational biologists building single-cell pipelines, not listeners after a general intro to drug discovery. Key Takeaways - Chi-squared tests on cell clusters draw their statistical power from the number of cells, not the number of donors, so a single oversampled patient can produce the same p-value as a hundred-donor study. - Rituximab clears 100% of B cells from circulation yet does nothing for lupus because the disease-driving cells live in tissue, not blood, a lesson now shaping where Arda tests its own molecules. - Neighborhood analysis scores each cell by the donor identity of its nearest neighbours rather than forcing cells into predefined clusters, producing a continuous disease-enrichment map with no cluster boundaries. - When depleted cells regrow, they often come back without the trait that made them harmful in the first place, which means a handful of doses can hold a chronic disease in remission for months. Chapter Markers 00:00 Why cell depletion beats pathway blocking 01:05 Welcome Adam Freund to the show 01:30 From Calico Life Sciences to founding Arda 03:29 Why blocking one pathway rarely works 05:32 B-cell depletion as the proof of concept 08:14 Building a modular library of depletion tools 10:46 Single-cell sequencing removes the need for a hypothesis 11:43 Why clustering is a dial, not ground truth 15:24 The chi-squared trap in single-cell analysis 20:40 Neighbourhood analysis and donor-weighted scoring 23:44 Moving from enrichment to causality 26:32 Inside Arda's lead fibrosis program 30:33 Why solid tissue testing beats blood samples 34:25 Simulating depletion in spatial transcriptomic data 38:49 The case for intermittent dosing over daily pills 43:58 The data infrastructure behind Arda's platform 48:46 Where spatial and protein data are heading Useful Links & Resources - Adam Freund on LinkedIn: https://www.linkedin.com/in/adam-freund-0657654 - CorrDyn: https://corrdyn.com Connect With the Show - Host Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ - Host Ross Katz on X: https://x.com/brosskatz - CorrDyn on LinkedIn: https://www.linkedin.com/company/corrdyn/ If your team runs single-cell pipelines, how do you currently decide on the number of clusters, and have you ever checked whether your significance scales with donor count rather than cell count? Tell us in the comments; we're building a running list of data QA checks for biotech data science teams. Visit corrdyn.com to learn how CorrDyn can help your organization extract value from data.

Ross Halls is joined by Stuart Watson and Alex Jones to reflect on Ipswich Town's pre-season friendly win at Union Berlin.The boys reflect on the action, where the Blues secured a 4-2 victory thanks to goals from Jack Clarke, Emersonn, Dara O'Shea and Kasey McAteer.There's chat around Dara O'Shea's position, the left wing situation and who starts in midfield, as well as the stand-out performers in the German capital.Then it's onto the sexy stuff, with Town closing in on the signings of Julio Enciso and Abdoul Ouattara from Ligue 1 side Strasbourg.There's also some stories from the trip and the view of pre-season as a whole.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast -https://www.kingsofanglia.com/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ross Halls is joined by Stuart Watson and Alex Jones ahead of Ipswich Town's final pre-season friendly against Bundesliga side Union Berlin.Stood outside the Stadion An der Alten Försterei in Köpenick, the boys reflect on the latest transfer news, with Julio Enciso close to making his Portman Road return, bringing a Strasbourg team-mate with him to Suffolk.Then it's on to other business, including Bayer Leverkusen midfielder Exequiel Palacios, as well as the key areas of the squad that the Blues need to strengthen next.There's also a discussion about tomorrow's pre-season friendly, with some unique insight into Union Berlin and what we can expect in the German capital.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast -https://www.kingsofanglia.com/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

BUFFALO, NY — August 12, 2026 — A new #research paper was #published in Volume 18 of Aging on July 27, 2026, titled “Transcriptomic aging clock analysis identifies key genes in opioid dependence.” The study was led by first author Hai Duc Nguyen from the Division of Microbiology, Tulane National Biomedical Research Center, Tulane University. The corresponding author is Woong-Ki Kim, who is affiliated with the Division of Microbiology, Tulane National Biomedical Research Center, Tulane University, and the Department of Microbiology and Immunology at Tulane University School of Medicine. Opioid dependence is a chronic and relapsing condition associated with substantial health and societal burdens. Chronic opioid exposure can affect neuronal signaling, immune function, metabolism, and other biological processes, yet the molecular mechanisms underlying dependence remain incompletely understood. Increasing evidence also suggests that substance use disorders may be associated with molecular changes related to aging, raising questions about how chronic opioid exposure interacts with age-dependent processes in the brain. To investigate these relationships, the researchers conducted an in silico study integrating three complementary approaches: RNA sequencing-based transcriptomic profiling, transcriptomic aging-clock modeling, and analysis of previously published genome-wide association studies (GWAS). The transcriptomic analysis used a publicly available brain RNA-seq dataset containing 42 samples—21 healthy controls and 21 individuals with opioid dependence—while the genetic analysis incorporated findings from six independent GWAS. Full press release - https://www.aging-us.com/news-room/transcriptomic-aging-clock-reveals-age-related-molecular-patterns-in-opioid-dependence DOI - https://doi.org/10.18632/aging.206405 Corresponding author - Woong-Ki Kim - wkim6@tulane.edu Abstract video - https://www.youtube.com/watch?v=7VwU0mFGkbg Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206405 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, opioids, GWAS, transcriptomic clock To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

La investigadora del CNIO explica en Noticias Fin de Semana cómo se produce el eclipse total de Sol y qué efectos provoca durante los minutos de oscuridad.

La investigadora del CNIO explica cómo se produce el eclipse total de Sol y qué efectos provoca durante los minutos de oscuridad.

Mark Heath is joined by the returning Stuart Watson and the hairy Ross Halls to discuss all things Ipswich Town.We start with a surprise - and bittersweet - farewell to Wes Burns, before moving on to the latest sexy stuff, with Town adding Florentino Luis this week and closing in on Sasa Lukic.We reflect on the state of the squad currently too, and consider what else Town still need.Then it's onto thoughts from the Le Havre friendly win, a look ahead to this weekend's warm-up against Rayo Vallecano and news that an NBA legend has become a minority owner of the Blues.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast -https://www.kingsofanglia.com/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Rob René was a high-performing tech executive. Then came the diagnosis. This is what his daily routine looks like now - and the science behind every single choice. Life before cancer — and what "healthy" looked like then The diagnosis that forced a complete rebuild Red light therapy: daily non-negotiable Molecular hydrogen: what, when and why The other tips and tricks that keep Rob sane and healthy.

Las manos son una de las herramientas más extraordinarias de nuestro cuerpo. Gracias a ellas podemos trabajar, cocinar, escribir, crear, acariciar y comunicarnos. Sin embargo, también son una de las partes que más exigimos todos los días. Pasamos horas frente a la computadora, sujetando el celular o realizando movimientos repetitivos. Con el tiempo, estos hábitos pueden provocar molestias o lesiones como tendinitis o el síndrome del túnel carpiano. Estas y otras recomendaciones para el cuidado de tus manos, encuentra en este podcast de El Expresso de las 10, con la asesoría del Dr. Sergio Sánchez Enríquez, Médico con Especialidad en Ortopedia y Traumatología, Maestría en Farmacología y Doctorado en Biología Molecular en Medicina. Director de División de Ciencias Biomédicas del Centro Universitario de los Altos.

Rob Rene spent 25 years in enterprise tech before a cancer diagnosis sent him deep into the science of cellular energy. What he found might surprise you. In this episode: Red light therapy — what the science actually says 660nm vs 850nm — why the wavelength matters Photobiomodulation: mechanism not marketing Molecular hydrogen — the most underrated recovery tool you've never heard of Why your mitochondria are probably running on empty What NASA and the military already know about light  

Mark Heath is back with Alex Jones and Ross Halls to talk all things Ipswich Town after a busy weekend. The boys start with a look at the latest sexy stuff, with midfielder Florentino Luis set to arrive from Burnley for £16m, while George Hirst potentially heads for the exit door.Then we reflect on Saturday's friendly double-header, starting with Daizen Maeda and Cameron Humphreys impressing in a win at Wycombe, after a second string XI lost at Oxford.We finish with a look ahead to tomorrow's Le Havre warm-up back at Portman Road, plus a few tales from our mini KOA tour to Oxford.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.kingsofanglia.com/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Shira Boehler's family is full of doctors, and every one of them told her not to get the full-body MRI. She canceled the appointment repeatedly herself, until her husband rebooked it one time too many and she finally went.The scan found a 3.8 centimeter mass in her right lung and labeled it a minor finding, with a note to correlate with symptoms. She had none. She was running six miles a day, the picture of health, and had never smoked. A follow-up CT months later showed the mass had grown, and on the Monday she walked into a pulmonary specialist's office she was told she had an invasive adenocarcinoma. She told him it was probably an EMR error. One week later, surgeons removed half her right lung to treat her cancer.Samira Daswani, host of Patient from Hell and founder of Manta Cares, welcomes lung cancer survivor and bestselling author Shira Boehler for an eye-opening conversation on the part that comes after the story, which is why almost nobody in Shira's position gets caught this early. Screening guidelines currently cover people over 50 with a twenty-pack-per-year smoking history, and fewer than one in five of them actually get scanned, in part because the criteria require disclosing something patients are ashamed of. Shira has been working the problem from both ends since her treatment, negotiating cash prices at imaging centers down to a fraction of what she paid and funding new scans for people who can't cover them through the nonprofit organization she founded, Cancer Doesn't Care.In this episode, Samira and Shira discuss:Why lung cancer is often diagnosed too lateThe importance of early detection and low-dose CT screeningHow people who have never smoked can still develop lung cancerThe stigma surrounding lung cancer diagnosisCurrent lung cancer screening guidelinesInsurance coverage, healthcare access, policy reformHow artificial intelligence may improve cancer screeningWhy patient advocacy is becoming increasingly important in modern healthcareChapters00:00 Introduction01:00 The Full-Body Scan That Changed Everything03:32 Diagnosed With Lung Cancer Despite Having No Symptoms05:30 Access, Privilege & Why Early Detection Isn't Equal07:10 Building the Cancer Doesn't Care Foundation09:21 Why Lung Cancer Screening Needs to Change10:19 Breaking the Stigma Around Lung Cancer12:26 Who Actually Qualifies for Screening?14:23 Changing Public Perception Through Advocacy16:20 Why Patients Must Advocate for Themselves17:15 AI, False Positives & the Future of Cancer Screening20:27 Why Lung Cancer Is Often Diagnosed Too Late21:17 Stage 1 vs. Stage 4 Survival Rates23:25 Shira's Advice for Anyone Considering Lung Cancer ScreeningShira Kupperman Boehler is a finance professional, health advocate, bestselling author, and lung cancer survivor. Shira holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. Alongside her husband Adam, she has spent her career building and scaling multibillion-dollar healthcare businesses, developing deep relationships across health systems, payers, and policymakers.After being unexpectedly diagnosed with Stage 1B lung adenocarcinoma despite never smoking and having no symptoms, Shira founded Cancer Doesn't Care, a nonprofit dedicated to expanding access to life-saving lung cancer screening and reducing financial barriers to early detection. She is also the author of the bestselling memoir One Scan Saved My Life, with proceeds supporting patient screening initiatives.

Mark Heath is joined by Alex Jones to discuss all things Ipswich Town after their friendly defeat to Osasuna.The boys start by discussing many different parts of Gary O'Neil's post-match press conference, which was full of interest and detail.We cover Jaden Philogene's future, Town's impending transfer business, injuries to Azor Matusiwa and Jack Taylor and the interest in Julio Enciso.Then it's onto who will end up as Town's starting goalkeeper and our thoughts on last night's game, including Abdul Fatawu's exciting debut, another look at Emersonn and Chuba Akpom's potential role.We finish with a look ahead to this weekend's friendly double header, an argument about tall people and Mark's Town-themed dream.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Send us Fan MailThis week on Translational Conversations, we talk with Dr. Zoe Donaldson, a prairie vole researcher, and Dr. Katherine Shear, a human researcher, about how their work has inspired and influenced each other's research on attachment bonding, love and loss, and the development of Prolonged Grief Disorder. In this episode, Dr. Donaldson and Dr. Shear discuss the role of the brain's reward system in grief, how grief differs from depression, the special bonding of prairie voles that makes them an ideal species for studying grief, and how their complementary research has inspired novel treatments for Prolonged Grief Disorder. Their discussion further explores the bidirectional process of translational research, how to consider the language we use when communicating findings from different species, and ways we can build better bonds between researchers to advance scientific progress. We thank Dr. Zoe Donaldson, the Larry Gold Professor in the Department of Molecular, Cellular, and Developmental Biology and the Department of Psychology and Neuroscience at the University of Colorado Boulder and Dr. Katherine Shear, the Marion E. Kenworthy Professor of Psychiatry at Columbia University and the founding Director of the Center for Prolonged Grief at Columbia School of Social Work, for their openness and willingness in discussing their research with us for this podcast.Translational Conversations is made possible through support from Biomedical Research Awareness Day, a program of Americans for Medical Progress and the American College of Neuropsychopharmacology.Resources & Links: Craving Love? Enduring grief activates brain's reward center by Mary-Frances O'ConnorNeurobiology and treatment advances for prolonged grief disorder by Donaldson and ShearPrairie Voles as a model of adaptive reward remodeling following loss of a bonded partner by Sadino and Donaldson Support the showFollow Lab Rat Chat on X! Facebook! Instagram!https://twitter.com/thelabratchat https://www.facebook.com/labratchat https://www.instagram.com/thelabratchat All Lab Rat Chat episodes are edited by Audionauts: https://audionauts.pro/ 

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USAFeaturing: Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USARamez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Mark Heath is joined by Alex Jones and Ross Halls to talk all things Ipswich Town on the latest KOA podcast. We start with news of the launch date for the new KOA website and app, before moving onto the slew of signings in the door this week.We discuss each of Issa Diop, Abdul Fatawu and Kayne van Oevelen, plus the incoming Daizen Maeda, and share our thoughts on each, plus where they will fit in at the Blues.Then it's onto the latest links and updates, including Hidemasa Morita, Kjell Scherpen and Breel Embolo, plus Sammie Szmodics.We finish with a bit of fun around FPL prices and chat about Saturday's first pre-season friendly out in Spain.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

What if the future of industry isn't giant factories, but molecular machines too small to see? DNA factories could repair bodies, grow habitats, and transform civilization.Get Nebula using my link for 50% off an annual subscription: https://go.nebula.tv/isaacarthurWatch my exclusive video Colonizing Ocean Worlds: https://nebula.tv/videos/isaacarthur-colonizing-ocean-worlds-subaquatic-settlementsCheck out Gods & Monsters: https://nebula.tv/curiousarchive/gods-and-monsters?ref=isaacarthur

What if the future of industry isn't giant factories, but molecular machines too small to see? DNA factories could repair bodies, grow habitats, and transform civilization.Get Nebula using my link for 50% off an annual subscription: https://go.nebula.tv/isaacarthurWatch my exclusive video Colonizing Ocean Worlds: https://nebula.tv/videos/isaacarthur-colonizing-ocean-worlds-subaquatic-settlementsCheck out Gods & Monsters: https://nebula.tv/curiousarchive/gods-and-monsters?ref=isaacarthur

Nels and Vincent discuss molecular mimicry of a pathogen virulence target by a plant immune receptor. Hosts: Nels Elde and Vincent Racaniello Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiEVO Links for this episode Join the MicrobeTV Discord server Molecular mimicry of a pathogen virulence target by a plant immune receptor (Science) Timestamps by Jolene Science Picks Nels – Plug-in solar Vincent – This Engine Will Reinvent Space Travel Music on TWiEVO is performed by Trampled by Turtles Send your evolution questions and comments to twievo@microbe.tv

With 8 billion imaginations in the world, Dr. Martin Burke calculates that the number of specialists who are able to create molecules can fit into a single building. On this exciting episode of Let's Talk Chemistry edited by Presley Vu, hosts Nina Deng and Poorvi Iyer talk with Dr. Burke, Professor of Chemistry at the University of Illinois Champaign and Founding Director of the Molecule Maker Lab. Dr. Burke is known for pioneering BLOCC chemistry, a modular approach to synthesis that opens up molecule building to non-specialists, robotics, and AI. This has paved the way to creating new treatments and digital platforms where making molecules become easily programmable and accessible to anyone. We hope you enjoy!

BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta Cancer Center at Brown University. Patients who develop multiple primary cancers face unique diagnostic and treatment challenges because each tumor may have distinct biological characteristics requiring different therapeutic approaches. Advances in genomic profiling and precision oncology now enable clinicians to better distinguish between independent tumors and recurrent disease while identifying molecular alterations that may guide individualized treatment strategies. This case report demonstrates how an international molecular tumor board integrated comprehensive genomic data with multidisciplinary expertise to develop personalized recommendations for a patient with an exceptionally complex cancer history. The case describes the clinical journey of a 48-year-old woman carrying a germline BRCA1 mutation who developed multiple primary cancers over nearly two decades, including breast cancer, basal cell carcinoma of the skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel adenocarcinoma. During this time, she underwent multiple surgeries, chemotherapy regimens, targeted therapy with the PARP inhibitor niraparib, and extensive molecular testing to characterize each malignancy. Full press release - https://www.oncotarget.com/news/pr/international-molecular-tumor-board-explores-personalized-treatment-strategies-for-a-patient-with-multiple-primary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28899 Correspondence to - Wafik S. El-Deiry - wafik_el-deiry@brown.edu Abstract video - https://www.youtube.com/watch?v=4KIDbmq6ui8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28899 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Ross Halls is joined by Alex Jones for a Monday edition of Ipswich Town Transfer Talk.The boys reflect on a busy weekend of news, with deals agreed for Leicester City star Abdul Fatawu and Fulham defender Issa Diop.Then it's onto the Blues' interest in Dutch goalkeepers Kayne van Oevelen and Kjell Scherpen, playing at FC Volendam and Union SG respectively.There's also talk about Hidemasa Morita, the Japanese midfielder in talks over a switch to Portman Road after leaving Sporting CP.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ex Ipswich Town chairman David Sheepshanks is feeling good about the future of his beloved Blues. Stuart Watson caught up with the former Town chief to discuss his new book, ‘Man on a Mission: The Agony and Ecstacy of a Life in Football'.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Beyond Traditional Medicine: The Science of Regeneration & Cellular Health with CEO Mick Emandi and Dr. Greg Carder Is regenerative medicine the future of healthcare—or one of the most misunderstood fields in modern medicine? In this thought-provoking episode of The Hurricane H Show, Hurricane H is joined by Mick Emandi, CEO of Regen MDs, and Dr. Greg Carder for an in-depth conversation exploring the rapidly evolving world of regenerative medicine, stem cell therapies, molecular hydrogen, and cellular health. Drawing from decades of healthcare leadership and clinical experience, Mick shares why he shifted his focus toward regenerative therapies after seeing countless patients exhaust traditional treatment options. Together with Dr. Carder, we examine the science behind stem cell technology, hydrogen inhalation therapy, inflammation, recovery, mitochondrial function, and the body's remarkable ability to heal. This balanced discussion separates science from hype, addresses common misconceptions, and explores how emerging evidence-based therapies may reshape the future of personalized healthcare, longevity, and wellness. Ultra RSF1 - Beyond Stem Cells & Exosomes - Ultra RSF-1 Regen MDs Care - Regen MDs THE EMBC NETWORK - YouTube THEEMBCNETWORKOFFICIAL - YouTube Topics Covered ✔️ Regenerative medicine explained ✔️ Stem cell therapy: Facts vs. myths ✔️ Molecular hydrogen & hydrogen inhalation therapy ✔️ Mitochondrial and cellular health ✔️ Chronic pain, inflammation & recovery ✔️ Evidence-based healthcare innovation ✔️ Patient-centered regenerative medicine ✔️ Longevity and the future of wellness An insightful conversation for anyone interested in the future of healthcare, performance, and living healthier through science-driven innovation.

Beyond Traditional Medicine: The Science of Regeneration & Cellular Health with CEO Mick Emandi and Dr. Greg Carder Is regenerative medicine the future of healthcare—or one of the most misunderstood fields in modern medicine? In this thought-provoking episode of The Hurricane H Show, Hurricane H is joined by Mick Emandi, CEO of Regen MDs, and Dr. Greg Carder for an in-depth conversation exploring the rapidly evolving world of regenerative medicine, stem cell therapies, molecular hydrogen, and cellular health. Drawing from decades of healthcare leadership and clinical experience, Mick shares why he shifted his focus toward regenerative therapies after seeing countless patients exhaust traditional treatment options. Together with Dr. Carder, we examine the science behind stem cell technology, hydrogen inhalation therapy, inflammation, recovery, mitochondrial function, and the body's remarkable ability to heal. This balanced discussion separates science from hype, addresses common misconceptions, and explores how emerging evidence-based therapies may reshape the future of personalized healthcare, longevity, and wellness. Ultra RSF1 - Beyond Stem Cells & Exosomes - Ultra RSF-1 Regen MDs Care - Regen MDs THE EMBC NETWORK - YouTube THEEMBCNETWORKOFFICIAL - YouTube Topics Covered ✔️ Regenerative medicine explained ✔️ Stem cell therapy: Facts vs. myths ✔️ Molecular hydrogen & hydrogen inhalation therapy ✔️ Mitochondrial and cellular health ✔️ Chronic pain, inflammation & recovery ✔️ Evidence-based healthcare innovation ✔️ Patient-centered regenerative medicine ✔️ Longevity and the future of wellness An insightful conversation for anyone interested in the future of healthcare, performance, and living healthier through science-driven innovation.

Beyond Traditional Medicine: The Science of Regeneration & Cellular Health with CEO Mick Emandi and Dr. Greg Carder Is regenerative medicine the future of healthcare—or one of the most misunderstood fields in modern medicine? In this thought-provoking episode of The Hurricane H Show, Hurricane H is joined by Mick Emandi, CEO of Regen MDs, and Dr. Greg Carder for an in-depth conversation exploring the rapidly evolving world of regenerative medicine, stem cell therapies, molecular hydrogen, and cellular health. Drawing from decades of healthcare leadership and clinical experience, Mick shares why he shifted his focus toward regenerative therapies after seeing countless patients exhaust traditional treatment options. Together with Dr. Carder, we examine the science behind stem cell technology, hydrogen inhalation therapy, inflammation, recovery, mitochondrial function, and the body's remarkable ability to heal. This balanced discussion separates science from hype, addresses common misconceptions, and explores how emerging evidence-based therapies may reshape the future of personalized healthcare, longevity, and wellness. Ultra RSF1 - Beyond Stem Cells & Exosomes - Ultra RSF-1 Regen MDs Care - Regen MDs THE EMBC NETWORK - YouTube THEEMBCNETWORKOFFICIAL - YouTube Topics Covered ✔️ Regenerative medicine explained ✔️ Stem cell therapy: Facts vs. myths ✔️ Molecular hydrogen & hydrogen inhalation therapy ✔️ Mitochondrial and cellular health ✔️ Chronic pain, inflammation & recovery ✔️ Evidence-based healthcare innovation ✔️ Patient-centered regenerative medicine ✔️ Longevity and the future of wellness An insightful conversation for anyone interested in the future of healthcare, performance, and living healthier through science-driven innovation.

Beyond Traditional Medicine: The Science of Regeneration & Cellular Health with CEO Mick Emandi and Dr. Greg Carder Is regenerative medicine the future of healthcare—or one of the most misunderstood fields in modern medicine? In this thought-provoking episode of The Hurricane H Show, Hurricane H is joined by Mick Emandi, CEO of Regen MDs, and Dr. Greg Carder for an in-depth conversation exploring the rapidly evolving world of regenerative medicine, stem cell therapies, molecular hydrogen, and cellular health. Drawing from decades of healthcare leadership and clinical experience, Mick shares why he shifted his focus toward regenerative therapies after seeing countless patients exhaust traditional treatment options. Together with Dr. Carder, we examine the science behind stem cell technology, hydrogen inhalation therapy, inflammation, recovery, mitochondrial function, and the body's remarkable ability to heal. This balanced discussion separates science from hype, addresses common misconceptions, and explores how emerging evidence-based therapies may reshape the future of personalized healthcare, longevity, and wellness. Ultra RSF1 - Beyond Stem Cells & Exosomes - Ultra RSF-1 Regen MDs Care - Regen MDs THE EMBC NETWORK - YouTube THEEMBCNETWORKOFFICIAL - YouTube Topics Covered ✔️ Regenerative medicine explained ✔️ Stem cell therapy: Facts vs. myths ✔️ Molecular hydrogen & hydrogen inhalation therapy ✔️ Mitochondrial and cellular health ✔️ Chronic pain, inflammation & recovery ✔️ Evidence-based healthcare innovation ✔️ Patient-centered regenerative medicine ✔️ Longevity and the future of wellness An insightful conversation for anyone interested in the future of healthcare, performance, and living healthier through science-driven innovation.

Mark Heath is joined by Stuart Watson and Alex Jones to discuss all things Ipswich Town on the latest KOA podcast.The boys start with very exciting news about our soon-to-be launched KOA app and website, before moving onto the latest sexy stuff.We discuss Town's interest in Abdul Fatawu, the noise around Jaden Philogene and a new link to a Dutch keeper. Then it's onto Mailbag, where we tackle questions ranging from our concern about Town's lack of signings so far to us fighting 10-year-olds.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ross Halls is joined by Alex Jones for the latest episode of Ipswich Town Transfer Talk.The boys start by assessing some of the big-name links, including Patrick Berg, fresh off his World Cup display against England. Young Premier League duo Marc Guiu and Mikey Moore are said to be Town targets as well.Then it's on to some slightly different rumours, including Anthony Musaba and talks of a £10m bid, as well as Southampton's negotiations for ex-Blue Ivan Azon.There's also chat around Elkan Baggott, Cieran Slicker and Conor Chaplin, who have all been on the move in the last few days.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Encore registration - "Piano Ten Thousand Leaves" was completed on May 16, 2026. And as a post-completion activity, I hope to deliver it to people 1000 years from now. And so, I have begun "Piano Ten Thousand Leaves - beyond completion -- The Millennium Forest --". I will not be creating any new songs, but I will select one song from the 4536 songs I previously created and re-register it here. ===================================================== 《ピアノ万葉集》は2026年5月16日に完結しました。 そして完結後の活動として、1000年後の皆様に届けたいと考えています。 そして、《ピアノ万葉集》完結世界 -- 深森千年紀 -- を始めています。 そして新しい曲は創りませんが、前に創っている4536曲の中から１曲を選んでここで再登録させて頂きます。 =========================== The Complete Works of Piano Ten Thousand Leaves Vol.3-2 =========================== #spotify: https://open.spotify.com/intl-ja/album/3Vm796tVBoyWIEp1mLOpD6?si=XAl79oycSLew593UEF2VkQ #AppleMusic: https://music.apple.com/us/album/the-complete-works-of-piano-ten-thousand-leaves-vol-3-2/6787596397 #amazonmusic https://amazon.co.jp/music/player/albums/B0H7PGFDNP?marketplaceId=A1VC38T7YXB528&musicTerritory=JP&ref=dm_sh_TvnOaWB0wpvmYJqquVwEz0Do6 ＃YoutubeMusic: https://music.youtube.com/playlist?list=OLAK5uy_nwzdnA7O232R4vuv1c1duYeQAx9i9Rtak&si=5ojmgsW5cxlv0h_h #LineMusic https://lin.ee/5SED98v #AWA https://s.awa.fm/album/17c47b59557f20fb0620?t=1783245626 --- All Music Streaming Services: 全曲視聴可能なのが嬉しいですね… https://linkco.re/rqBErhU1 =========================== The Complete Works of Piano Ten Thousand Leaves Vol.3-1 =========================== VOLUME3-1 just released! Gentleness, carried on 4,536 leaves of sound. #spotify: https://open.spotify.com/intl-ja/album/5aSDLOUFLgmoK0Nu5uYvxK?si=FxFC1shbTNmcVsbGuZzufw #AppleMusic:  #amazonmusic https://amazon.co.jp/music/player/albums/B0H6VDD1KC?marketplaceId=A1VC38T7YXB528&musicTerritory=JP&ref=dm_sh_Ke44Vvf27v9Scn17Q3GlghCkH ＃YoutubeMusic: https://music.youtube.com/playlist?list=OLAK5uy_keXkSwBS2JvaxE-tEwAuXmIOe4CzSijgY&si=tJYfAwa-8cQ8sUyh #LineMusic https://lin.ee/pOzyULD #AWA https://s.awa.fm/album/95f94c20e913e538ed09?t=1782684025 --- All Music Streaming Services: 全曲視聴可能なのが嬉しいですね… https://linkco.re/AAZ0NrcQ

Molecular farming has the potential to add a new layer of value to existing operations without requiring major operational changes.

Ross Halls caught up with former Ipswich Town forward Paul Goddard to discuss his time at Portman Road and journey in football for the latest of our Kings of Anglia podcast specials.Paul spoke about a range of memories, including getting into football, playing for the likes of QPR, West Ham, Newcastle Derby County and Millwall.Then it's onto his spell at Town from relationship with John Lyall, his Sarge nickname, winning the Second Division title, playing in the Premier League, being joint-caretaker manager with John Wark and becoming a coach.The duo also discuss life in Suffolk, being an football agent and what the future holds.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00) Molecular analyses in the assessment and management of endometrial cancer (07:33) CME information and select publications

Ross Halls is joined by Stuart Watson for the latest episode of Ipswich Town transfer talk.The boys start by discussing Hearts striker Cláudio Braga, whom Town have reportedly 'entered the race' to sign and a new goalkeeper link in Kjell Scherpen.Then it's onto some other interesting names, with the Blues said to be rivalling Hull City for Lazio left-back Luca Pellegrini, while Simon Adingra has also been linked.There's also chat around Jaden Philogene switching his agency and if that means he could leave Portman Road this summer.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

Mark Heath is joined by Stuart Watson and Ross Halls to discuss all things Ipswich Town as business picks up at the Blues.We start with the impending arrival of Brazilian striker Emersonn, who looks set to sign in a club record deal.Then it's onto the return of Wes Burns and the impact he can have in the Premier League, before we chat about the new home and away kits which were released last week.We finish with the departure of Martyn Pert and many of McKenna's backroom staff, plus the start of pre-season.And we have news of a big KOA milestone!Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ross Halls caught up with former Ipswich Town forward Jack Lankester to discuss his time at Portman Road and journey in football for the latest of our Kings of Anglia podcast specials.Jack spoke about a range of memories, including getting into football, joining Town's academy aged seven, being a fan and progressing through the youth ranks. He chats about which senior players helped him, making his debut under Paul Hurst, relationship with Paul Lambert, goal against Millwall and long term back injury.The duo also discuss his return to action, being sold by Paul Cook, career since he departed Town and what the future holds.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Send us Fan MailThis week, we ask the important questions about B5 season 5, episode 16, "And All My Dreams Torn Asunder". Mike is a bitch when the edible finally hits, Joe's got rants in his pants, and Sarah goes on a button hunt. Spoiler-free discussion: 0:00:00 - 52:50Spoiler Zone: 52:50 - 55:08Next Episode and other Shenanigans: 55:08+Music from this episode:“Surf Punk Rock” By absentrealities is licensed under CC-BY 3.0“Please Define The Error” By Delta Centauri is licensed under CC-BY 3.0“The Haunted McMansion” By Megabit Melodies is licensed under CC-BY 3.0

Ross Halls is joined by Alex Jones for the latest episode of Ipswich Town Transfer Talk.The boys start by discussing veteran striker Callum Wilson and Juventus defender Lloyd Kelly, both named in Stuart Watson's exclusive story from last week.Then it's onto some other interesting names, with the Blues said to be rivalling Hull City for Brazilians Alexsandro and Emersonn, with Guillaume Restes also linked.There's also chat around Torino's Cesare Casadei, ex-Wolves skipper Max Kilman, and Southampton wide man Tom Fellows.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ross Halls is joined by Alex Jones for the latest edition of the Kings of Anglia Ipswich Town podcast.The boys share their thoughts on the new kits for the 2026/27 Premier League season.Plus take questions and thoughts from fans watching live.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

ReferencesNeuroendocrinology. 2000 Mar;71(3):187-95J Immunol.2014 Jan 3;192(3):979–984.Molecular and Cellular Endocrinology 2018.Volume 472, 5 September: 40-49Front. Immunol., 2023. 16 March Sec. T Cell Biology.Volume 14 -Guerra, DJ. 2026. Unpublished Lectures.Emerson/Lake/Palmer. 1972. Trilogy lp. fullhttps://music.youtube.com/playlist?list=OLAK5uy_m-KrYKLiBdrOau11bsTte7M4qSR0en7VI&si=DwpdwN0nR_IGNsK1

This episode has a fun personal twist: There's a counterfactual world where I was employee #1 at Genesis Molecular AI, the company behind today's episode. A certain introduction happened a few weeks too late and I had already happily signed at Atomwise, another ML-for-drug-discovery startup. Same problem, different company. I was certain ML was going to transform small molecule drug discovery. Early results were underwhelming. Useful at times, but nowhere near revolutionary. In the last year I've seen signs that ML is finally ready to deliver on my convictions from a decade ago. Genesis is one of the places that might have finally cracked this problem. I was super excited to come full circle and catch up with co-founder Evan Feinberg and CTO Sergey Edunov.If you are at all interested in small molecule drug discovery, we think you will find this fascinating!In our nearly two hour chat we cover:* What is small molecule drug discovery, and why is it hard* Structure prediction as a hotbed of innovation in AI algorithms* How advances in AI elsewhere have enabled stepwise improvements in predictive power* How the community benchmarks are essentially calling AI slop good enough* The Genesis flagship model (PEARL) can routinely hit a threshold that is necessary for real-world applications* New agentic workflows enabled by these highly accurate modelsRead on for more, and also some personal thoughts on the future at the end.The coolest diffusion research is happening at GenesisSergey Edunov came to Genesis from Meta where he led Llama 2 training and Llama 3 pretraining. Sergey was a former physicist who thought he was done with physics after many years of training LLMs. Then, he discovered Genesis, and was blown away with all the novel architecture work they've been developing.It probably surprises no one that modern LLM research has not resulted in fundamentally novel or exciting updates in architectures since almost the advent of the transformer — the entire field is using variants on the same idea that came out in the original “Attention is all you need” paper. Sure, some were quite useful (mixture-of-experts in particular allowed for the massive model paradigm we're at today), but there was very little conceptually exciting.“We sort of had to wait for the right primitive to get created, and that turned out to be diffusion… Actually, some of the most innovative diffusion research that's happening in our field is happening in 3D structure prediction right now.” — Evan FeinbergThe field of 3D structure prediction on the other hand has been a hotbed of research. Genesis' recent model PEARL (Place Every Atom at the Right Location) is able to understand protein flexibility, and model not just where the ligand goes, but also make small adjustments of the protein so that the two fit better than either alone. The field knew this was missing for a long time, but it was really hard to model until now.Agentic DiscoveryWhat makes this problem so hard? As Sergey points out, there are 10^60 possible drug-like small molecules. You'll never be able to search them all, and trying to find the good ones is something like finding a needle in a haystack — except everything except your needle is dangerous.“There are 10 to the 60 drug-like small molecules in the universe… it's like finding a needle in a haystack, where everything except your needle is very, very dangerous.” — Sergey Edunov“Or finding hay in a needle stack might be a more apt analogy.” — Evan FeinbergTrying to solve the multi-parameter optimization problem is even worse. What makes a strong binder and a molecule with good “ADMET Properties” are oftentimes at tension with each other. For example, a good binder is likely greasy, but a greasy molecule is likely insoluble so it won't enter the bloodstream and get to where it needs to go!Genesis' advances in generative AI have now pushed them beyond the threshold where they believe agentic drug discovery loops are finally possible. We all remember the early days of LLMs. They were great chatbots but terrible agents, as small errors compounded rapidly into uselessness. As LLMs got better, the usefulness of agents rapidly improved. Evan and Sergey argue that their models at Genesis recently passed a similar threshold. Their internal agentic drug-discovery system (code named SAPPHIRE) can now iterate like a chemist: look at and reason about poses, form hypotheses, read literature, use internal tools, create candidates for the next iteration. Combining this with automated lab partnerships like the one Genesis has with Incyte, we're rapidly approaching a time of drug discovery agents running 24/7 making/testing new molecules. Exciting times!Benchmark crisis: Everyone's favorite benchmark is slopOne surprising point that isn't talked enough about: the academic field of “co-folding” has settled on a benchmark value of “2 Angstrom RMSD” as a metric for a “good pose”. Evan does not mince words: this threshold is just bad. Perhaps even deceptively bad. For many strong binders, there's a very clear pose, one that you can even directly resolve in the PDB electron density! And yet, with a 2Å RMSD threshold, you can get the pose quite wrong in ways that might even mislead a medicinal chemist. For example, flip around an aromatic ring, and everything looks reasonable, but you're no longer modeling the right interactions.Evan makes the strong claim that 1Å RMSD is really the threshold necessary to ensure the core of the molecule is sitting where it needs to be, and models all interactions.“If your model is sitting at 1.8, 1.9 Angstrom RMSD, that's slop, most likely.” — Evan FeinbergAs a simple example, he points out hydrogen bonds which are responsible for many of the most important interactions in protein-ligand systems. Hydrogen bonds only have a 0.6Å range to be valid! Clearly if you're accurately resolving all H-bonds, you generally have to be doing much better than the 2Å threshold.This is clearly a hard-fought lesson for Evan and Genesis. In their opinion, the community is stuck on these benchmarks because academics developing methods were not users. Evan does see signs of life, with the use of new metrics such as lDDT for co-folding. Hopefully soon the community can agree that “1.8Å RMSD is slop”, and start hill climbing on this much harder task.For a more thorough exploration of the weaknesses in conventional benchmarks, see the PEARL technical report.PEARL tops OpenBindWhich makes what happened next all the more striking. Near the end of the podcast, we talked about a recent “proof-is-in-the-pudding” moment for Genesis — evaluating their PEARL model on a recently released OpenBind benchmark. This benchmark featured 802 never before seen co-complexes on a target protein EV-A71. This target seems almost custom-chosen to give most classical docking methods a problem. When a ligand binds to the main binding site, the protein moves around to close off the path the ligand used to enter the binding pocket. This process, known as “induced fit” is notoriously hard for traditional methods to model. The tradeoff is easy to understand: treating the protein as a static structure, it becomes difficult to place a ligand in a binding pocket. Treat the protein as dynamic, and now you have to simulate complicated processes that take a long time to resolve.PEARL was able to model the induced fit of the ligand without running long MD simulations. Across the different evaluation metrics, PEARL came out not just ahead, but oftentimes well ahead of any public model. A truly impressive result.“Where PEARL was exceptionally good is figuring out how to move this loop. We are basically correct for every single pose.” — Sergey EdunovEven more exciting, this was done without any fine-tuning, or using any data on the target or homologous targets — the template PDB was released after PEARL's training cutoff.Where does co-folding go now?As someone who has followed or participated in ML techniques for protein-ligand interactions for almost a decade, I was genuinely impressed with the results that Genesis has released recently. This has been many years in development, and I'm sure Evan and the team had many sleepless nights trying to get to this point. I also think other teams are making similar progress — both Isomorphic and Deep Origin have released results that seem spiritually similar and combine computation, wetlab data, ML, to achieve genuine predictive power that seemed impossible a decade ago. Sadly, all of the above are closed source so there's no way to honestly compare them. Looking at the results I think there might be a time in the not so distant future where we can consider protein-ligand binding “solved”.I sincerely hope that the academic community can take inspiration from these developments. Once you know something can be done, it's much easier to execute. Still, I believe that the key enabler in all of the above was the tight integration of ML, large-scale computation, and real-world drug discovery applications. Sadly academia is just not structured in a way that makes such a development easy.With those parting thoughts, we hope you give the podcast a listen! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Ross Halls is joined by Stuart Watson and Alex Jones for the latest edition of the Kings of Anglia Ipswich Town podcast.The boys complete the great squad audit of 2026, looking at every player who could be involved for the Blues in the Premier League next season.There are decisions to be made. Who stays in the squad, who gets a loan move, and who will move on permanently this summer? There's plenty of debate as we go through every position.There's also a look at who will fit Gary O'Neil's style of play and how many new signings will be needed as Town prepare to tackle the top flight.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Ross Halls caught up with former Ipswich Town loanee Jonny Williams to discuss his time at Portman Road and journey in football in our Kings of Anglia podcast special.Jonny spoke about a range of memories, including his early days in football, starting out at Crystal Palace, breaking into the first-team, winning promotion and joining Town on loan.He chats about his relationship with Mick McCarthy, key memories, injury set-backs, potential of a permanent move, 'Joniesta nickname' and overall time in Suffolk.The duo also discuss playing for Wales at major tournaments, being a free agent and what the future holds.Kings of Anglia is sponsored Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Elo Life Systems: https://elolife.com/Super excited to bring on Matt DiLeo of ELO Life Systems on today's episode. Some of you may remember that ELO Life CEO Todd Rands was a part of 412 of this podcast two years ago. I've been fascinated by their work ever since to bring to the market what they call molecular farming. Matt does a great job of explaining the concept and how this shifts the value in some ways from food processors back to the farm by allowing farmers to grow desirable healthy ingredients inside of the commodity crops they already grow. It's kinda mind blowing. Some background on Matt: Dr. Matt DiLeo serves as the vice president of research & development at Elo Life Systems. In his role, Matt applies agricultural OMICs and precision breeding technologies to advance Elo's product pipeline. Prior to joining Elo, Matt held scientific leadership roles at Novozymes and KeyGene USA. Matt received his Ph.D. in Plant Pathology from UC Davis and completed a postdoc at the Boyce Thompson Institute, where he studied the impact of silencing regulatory genes on the nutritional composition of the tomato fruit metabolome.Matt seems to have a knack for being on the cutting edge of ag science and technology and has shown this in a variety of areas throughout his career.

Molecular hydrogen improves your body's antioxidant defenses instead of directly lowering oxidative stress, helping you recover without blocking muscle adaptation Molecular hydrogen helps you maintain speed and power during repeated sprints, especially in the final, fatigue-heavy stages where performance normally declines Hydrogen supports your cellular energy systems by improving mitochondrial function, allowing your muscles to maintain power under stress Unlike traditional antioxidants, hydrogen targets only the most damaging molecules, preserving the signals your body relies on to build strength and endurance Using hydrogen in short, repeated doses, especially through hydrogen-rich water, strengthens your body's resilience and speeds recovery over time

The current Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda is caused by the Bundibugyo virus. There's no specific treatment or vaccine for this strain, unlike the more common Zaire strain that caused the 2014 outbreak.  Molecular biologist Christian Happi has dedicated his career to improving genomic sequencing capabilities and virus monitoring across the continent of Africa. He joins Flora to discuss the challenges of the current outbreak and his vision for better disease surveillance.  Guest: Dr. Christian Happi is a distinguished professor at Redeemer's University and runs the Institute of Genomics and Global Health in Nigeria. Other episodes you may enjoy: Inside the Nebraska quarantine facility responding to hantavirus Can ‘Suggestion-Box Science' Make Public Health More Useful? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.